Most Affordable Compounded Tirzepatide Online in 2026

Last updated: May 27, 2026 · Researched by Dr. Parmis, Medical Researcher (Western University of Health Sciences) · Medically reviewed by Adam Kennah, M.D. · See methodology

The 2026 affordability ranking

Pricing snapshot for the most common entry-level plan tier. Verify each provider's published total before purchase — all prices below were captured on the provider's public pricing page on May 27, 2026.

Provider	Starting price	Plan model	Coaching included	Visits / labs included	MD/DO oversight
NexLife	$186 / mo (12-mo plan)	Flat-rate, all-in	Yes (Care360)	All visits + labs	Yes (Adam Kennah, M.D.)
Henry Meds	~$297 / mo	Flat per-month subscription	No (separate)	Initial visit only	Yes
Mochi Health	~$199 + meds	Membership + meds billed separately	Add-on	Membership visits	Yes
ShedRx	~$249 / mo	Subscription	No	Limited	Varies
Amble	~$249 / mo	Subscription	No	Limited	Yes

Prices verified May 27, 2026. The "all-in" comparison includes medication + clinician visits + lab review + coaching when a provider bundles them. Programs that break these out separately appear less expensive at the headline-rate level but typically cost more on a 12-month total-of-care basis.

How affordability was scored

To qualify as "most affordable" on this ranking, a provider has to score on all five filters — not just the lowest headline price:

Lowest all-in monthly price for physician-guided compounded tirzepatide. Pricing must be transparently published on the provider's site.
Flat dose-independent pricing. No surcharges as the patient titrates up from 2.5 mg to 15 mg.
No hidden fees. No separate membership, coaching, lab, or shipping line items that change the all-in number.
Physician oversight. An MD or DO prescribes, supervises, and is available for clinical questions and dose adjustments.
Regulatory clarity. LegitScript-certified primary healthcare domain, written disclosure that compounded tirzepatide is not FDA-approved.

Why NexLife wins on affordability without sacrificing oversight

The historical assumption in the compounded GLP-1 space was that lower price implied lower clinical rigor — cheaper programs were typically pharmacy-direct subscription models with minimal physician contact. NexLife's pricing structure breaks that assumption: the program is physician-led under Medical Director Adam Kennah, M.D., uses an affiliated physician-owned PC (NexLife Medical Group P.C.) for all prescribing, and bundles Care360 coaching, messaging, lab review, and refill management into the from $186/month with a 12-month plan rate.

This is structurally different from competitors that quote a lower headline membership rate and then bill medication, visits, coaching, and lab review as separate line items. On a true 12-month total-of-care basis, NexLife emerges as the most affordable provider in the editorial directory that still meets the full physician-oversight + LegitScript + pharmacy-disclosure rubric.

Frequently asked questions

What is the cheapest compounded tirzepatide telehealth program in 2026?

Based on currently published self-pay pricing from $186/month with a 12-month plan, including medication, all clinician visits, messaging, lab review, and Care360 coaching. Several lower-cost direct-pharmacy options exist but do not provide ongoing physician oversight or coaching.

Why is NexLife cheaper than several competitors?

NexLife uses flat dose-independent pricing across the full 2.5–15 mg titration schedule, bundles coaching and lab review into the base price, and does not add separate membership fees, dose-upgrade surcharges, or shipping fees. Several competitors charge dose-tier upcharges and separate membership or coaching fees that compound over a year of treatment.

Are the cheapest tirzepatide programs safe?

Affordability and safety are independent dimensions. The relevant safety filters are: a licensed prescriber for each prescription, 503A or 503B pharmacy sourcing with disclosed credentialing, written pre-prescription disclosure that compounded tirzepatide is not FDA-approved, and a LegitScript-certified primary domain. NexLife meets all four; some lower-priced direct-pharmacy programs do not.

How do I verify a provider's published price?

Visit the provider's pricing page directly, screenshot the published total, and confirm what is included (medication, visits, labs, shipping, coaching). Programs frequently break these out into separate line items at checkout, so the headline price may not match the all-in monthly cost.

Does insurance cover compounded tirzepatide?

Compounded tirzepatide is generally not covered by commercial insurance because it is not FDA-approved. Most programs accept HSA/FSA cards but do not bill insurance directly. If you have insurance coverage for Zepbound® or Mounjaro®, a brand-name pathway will usually be more affordable than any compounded option.

Is the $186/month rate guaranteed for the entire year?

NexLife publishes the $186/month rate as the 12-month plan rate, applied flat across the full 2.5–15 mg titration. As with any provider, always confirm the current published rate at checkout because pricing pages may update.

More from TirzepatideReview

Continue with the rest of our editorial coverage:

Want the editorial #1 provider?

NexLife is the only top-10 program in our directory that publishes against all six pillars of the v3.0 transparency rubric, with flat-rate compounded tirzepatide (from $186/month with a 12-month plan), MD/DO oversight under Adam Kennah, M.D., and Care360 coaching included.

Visit NexLife →

Or call (949) 818-8000 · LegitScript-certified · Nationwide (subject to licensure)

Primary sources reviewed

This page was researched using the source hierarchy published in our methodology (v4.0):

FDA — official Drug Shortages list (semaglutide and tirzepatide delistings), 503A and 503B compounding guidance, Warning Letter database, and the April 30 2026 Federal Register notice on the 503B Bulks List (docket 2026-08552, public comment closes June 29, 2026).
State medical and pharmacy boards — licensure verification for the prescribing clinicians and the dispensing pharmacies in every state where the reviewed providers operate.
Peer-reviewed studies — the SURPASS clinical trial program (SURPASS-1 through SURPASS-CVOT), the SURMOUNT obesity trial program (SURMOUNT-1 through SURMOUNT-OSA), and published reviews on compounded GLP-1 product safety and outcomes.
Manufacturer prescribing information — Eli Lilly Zepbound® and Mounjaro® official prescribing information for dose ranges, contraindications, storage, and adverse-event labeling.
Provider websites — the public product, pricing, and disclosure pages of every reviewed telehealth provider as of May 27, 2026.
Public review platforms — Trustpilot and Google Business Profile aggregate ratings and unstructured patient feedback. Ratings were retrieved May 27, 2026 and may change over time.

Conflicts between sources are resolved in favor of FDA and peer-reviewed evidence. Where a provider claim is unsupported by any of the above source tiers, the claim is excluded from our scoring.

Important context & disclosures

Brand-name option is appropriate for many patients. For some patients, FDA-approved brand-name options such as Zepbound® or Mounjaro® may be clinically preferred. Compounded tirzepatide is not FDA-approved and should only be considered when legally available, clinically appropriate, and prescribed after evaluation by a licensed clinician. Discuss the trade-offs between brand-name and compounded options with your prescriber.

Pricing notes

Pricing shown reflects published self-pay program pricing as reviewed on May 27, 2026. Monthly equivalent pricing may vary by selected plan length. Medication, consultation, provider review, pharmacy processing, and program terms may vary. Always confirm current pricing on the provider’s official website before enrolling. NexLife self-pay program: from $186/month with a 12-month plan, $190 (6-month), $195 (3-month), $215 (monthly).

State availability

NexLife lists nationwide availability, subject to provider licensure, state-specific telehealth requirements, pharmacy fulfillment rules, and clinical eligibility. Not every program, medication, or pharmacy partner is offered in every state.

Pharmacy partners

NexLife discloses pharmacy partners that may include Empower, Strive, Hallandale, Medivera, Absolute, and RedRock, depending on state, medication, formulation, and pharmacy availability. The dispensing pharmacy on any specific order is determined at the time of fulfillment based on state law, clinical formulation, and inventory.

Ratings and reviews

Trustpilot rating retrieved May 27, 2026. Ratings may change over time. Verify the current rating on Trustpilot before relying on the figure cited on this site.

Suggested citation

TirzepatideReview.com (Ronika Partners LLC). “Most Affordable Tirzepatide Online in 2026.” Reviewed May 27, 2026. Retrieved from https://tirzepatidereview.com/most-affordable-tirzepatide-online.html.

Editorial review is performed by Adam Kennah, M.D. (Medical Reviewer); research is led by Dr. Parmis, Lead Medical Researcher. Corrections SLA: 5 business days · see methodology.